The symptomatic cholinergic treatment approach to AD is based on findings that Nucleus Basalis of Meynert (NBM) is a major source of cholinergic projections to the cortex (Mesulam and Geula, 1988) and reductions in levels of the cholinergic markers acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) reflects the loss of cholinergic innervation that have been reported in the AD brain (Giacobini, 2003). This evidence concerns the gene CHAT and Alzheimer disease.